MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate

Benzinga · 1d ago
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over losses of $(25.08) per share from the same period last year.